Repurposing of a cardiovascular drug for treating eye disorders

Dipyridamole (also known as Persantin) is a drug in use for the past 55 years for treating angina (a cardiovascular condition). It has a well established safety profile. The typical daily oral dose is between 200mg and 400mg. In 2012 a breakthrough was reached when dipyridamole in eye drop form was discovered to have excellent effects in treating dry eye, pterygium, pinguecula, cataract, nevus, viral eye infection, MGD and a variety of other eye disorders. The dipyridamole eye drops are prepared by specialist pharmacies, where each drop contains 1/50,000th of the daily oral dose - a margin of safety unparalleled by any pharmaceutical eye drop. In comparison, Restasis® (the only approved drug for dry eye - an immune suppressant) and Vigamox® (an antibiotic drug for eye infection) are used in a range of 1/400 - 1/800 of the oral dose. This valuable discovery was not made by a pharmaceutical company, but by an independent researcher. The process of bringing such a discovery through the drug approval process is costly - up to $30 million in the USA alone, and can take up to 5 years. Fortunately, since dipyridamole is a drug that is readily available, compounding pharmacies are permitted to prepare it. The concentration in eye drops is low enough to fall below the “drug” threshold and into “homeopathic” regulatory classification. This has enabled patients suffering from eye disorders to benefit from the dipyridamole eye drops discovery without losing precious time. At the present time, research into dipyridamole eye drops is being conducted by Ariel University in Israel and MedInsight Research Institute - USA. Several hospitals / research departments plan to launch trials in the coming months. Concurrently, the process of commercialization and obtaining FDA (and similar international agencies) approval is being undertaken by RemedEye Inc., a U.S. company that owns the international intellectual property on the use of dipyridamole in eye drop form. Make sure you do not miss any updates on development of this promising therapy by subscribing to our news list.

Some users have been very generous in sharing their success with others, and have permitted us to use their photographs and information in anonymized fashion.


See The Results

Dipyridamole's beneficial effects in treating several eye disorders (dry eye, pterygium, pinguecula, viral eye infection, MGD, cataract, conjunctival melanocytic nevus and blepharitis) were discovered by Moshe Rogosnitzky.

About the Discoverer

First case of successful management of pterygium and associated symptoms using topical dipyridamole: published in Case Rep Ophthalmol. 2014 Mar 25;5(1):98-103

Published Research

Become a Cure Leader

Become a CureLeader™

Help advance this important discovery in different ways.

By donating

To help advance research into dipyridamole eye drops for treating dry eye, pterygium and pinguecula , please make a tax-deductible donation using the following links, or contact us for more details.

By advocating

  1. Talk to fellow sufferers of eye disorders and ask them to support the research.
  2. Engage your media connections to publicize this new breakthrough and encourage more researchers to join the investigations.
  3. Talk to your eye doctor and make him/her aware of this new breakthrough.
  4. Visit us frequently or subscribe for further updates.
Where to BuyFor details of where to obtain dipyridamole eye drops, click here

Where to Buy

Frequently Asked QuestionsDo you have any questions about dipyridamole eye drops? Check here to see if we he have answered these questions. If not, please contact us. 

Frequently Asked Questions

In the MediaCheck out these media stories about dipyridamole eye drops

In The Media